Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$5.05 USD
+0.06 (1.20%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.02 -0.03 (-0.59%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Capricor Therapeutics, Inc. [CAPR]
Reports for Purchase
Showing records 1 - 20 ( 85 total )
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
2Q24 Results; Dynamic Discussions With FDA Continue Ahead of Planned BLA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
3-Year OLE Findings Highlight Sustained DMD Improvements; Pre-BLA Meeting in 3Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
Time Is Muscle; Time Is Now for Investment Case; 1Q24 Results
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
Who Doesn''t Like a Friendly FDA; CAP-1002 Path Even More Clear
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
2023 Results; It''s Getting Real For Patients and Investment Case; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
3Q23 Results; HOPE-3 Enrolled With Futility Analysis Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
Visibility Is Everything; HOPE-3 Path Set; Target Increased to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
2Q23 Results; Momentum Builds As HOPE-3 on Track to Complete Enrollment in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
1Q23 HVAC Checks: Res''l Markets Resilient; De- Stocking Unlikely in 1H23
Provider: KeyBanc Capital Markets
Analyst: HAMMOND J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
2022 Results; Further FDA Groundwork For BLA; HOPE-3 Interim Expected in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
3Q22 Results; Progress in CAP-1002 Phase 3 Raises Hopes for First Look in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
2Q22 Results; CAP-1002 Officially Pivotal As HOPE-3 Enrollment Cranks Up
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
12-month OLE Data Point to Lasting DMD Impacts; Phase 3 HOPE-3 Trial Open
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
1Q22 Results; Cash Strong and Going Pivotal Shortly
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
Who Said Patience Doesn''t Pay Off With Data? HOPE Finds a Champion; Price Target Increased to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
3Q21 Results; Pivotal HOPE-3 Ready for Prime Time; Who Takes it Forward is the Question Now
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
Critical Clarity Provided; Eyes Toward CAP-1002 Partnership Now; Target Increased to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
2Q21 Results; CAP-1002 Ready for Pivotal With FDA Feedback While Pipeline Develops
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
1Q21 Results; Active Therapeutic Pipeline Looks to Join the COVID-19 Fray
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J